Verification of new technology in new biological drug candidate
|Coordinator||ILYA PHARMA AB|
|Funding from Vinnova||SEK 3 500 000|
|Project duration||October 2017 - July 2018|
Purpose and goal
The overall aim with the project is to develop a new biologic medical product to treat large and chronic wounds. The goal is that the new treatment will bring clinical value both to patients with large and chronic wounds and to the health care system. This project is a subproject in a critical phase in the drug development where the technology is validated for safety and efficacy in large animals and healthy volunteers as well as industrialization and scaling of the manufacturing process.
Expected results and effects
The results from this project is in line with what is required in terms of regulations transitioning from a preclinical to clinical phase and in parallel developing the company and starting to plan the case for the finished product and market approval.
Planned approach and implementation
This project has two parts, one for planning, strategy (clinical and commecial), dissemination of results and to build a strong team. The other part concerns the execution of key activities in the drug development project. The SweLife project have progressed according to plan.